Rationale and design of a prospective, observational, multicentre study on the safety and efficacy of apixaban for the prevention of thromboembolism in adults with congenital heart disease and atrial arrhythmias: the PROTECT-AR study.
Title | Rationale and design of a prospective, observational, multicentre study on the safety and efficacy of apixaban for the prevention of thromboembolism in adults with congenital heart disease and atrial arrhythmias: the PROTECT-AR study. |
Publication Type | Journal Article |
Year of Publication | 2020 |
Authors | Kartas, A., Doundoulakis I., Ntiloudi D., Koutsakis A., Kosmidis D., Rampidis G., Apostolopoulou S., Frogoudaki A., Tzifa A., Avramidis D., Ntzoyvara O., Liori S., Mousiama T., Mouratoglou S. Anastasia, Karvounis H., & Giannakoulas G. |
Journal | BMJ Open |
Volume | 10 |
Issue | 9 |
Pagination | e038012 |
Date Published | 2020 09 22 |
ISSN | 2044-6055 |
Abstract | INTRODUCTION: The risk for stroke in adults with congenital heart disease (ACHD) is increased, especially in the setting of commonly ensuing atrial arrhythmias (AA), namely atrial fibrillation, atrial flutter or intra-atrial re-entrant tachycardia. Data are limited regarding treatment with non-vitamin K oral anticoagulants in long-term studies involving patients with ACHD and AA. |
DOI | 10.1136/bmjopen-2020-038012 |
Alternate Journal | BMJ Open |
PubMed ID | 32963069 |
PubMed Central ID | PMC7509965 |